tm-38837 tm-38837 tm-38837 is a small molecule inverse agonist/antagonist of the cb1 cannabinoid receptor, with peripheral selectivity. it is being developed for the treatment of obesity and metabolic disorders by 7tm pharma. the company has announced phase i clinical trials. tm-38837clinical dataatc codenoneidentifiers iupac name 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-n-(piperidin-1-yl)-1h-pyrazole-3-carboxamide cas number1253641-65-4pubchem cid49779607chemspider29361353chemical and physical dataformulac30h25cl2f3n4osmolar mass617.51 g·mol−13d model (jsmol)interactive image smiles o=c(c1=nn(c2=cc=c(cl)c=c2cl)c(c3=cc=c(c#cc4=cc=c(c(f)(f)f)c=c4)s3)=c1cc)nn5ccccc5 inchi inchi=1s/c30h25cl2f3n4os/c1-2-23-27(29(40)37-38-16-4-3-5-17-38)36-39(25-14-11-21(31)18-24(25)32)28(23)26-15-13-22(41-26)12-8-19-6-9-20(10-7-19)30(33,34)35/h6-7,9-11,13-15,18h,2-5,16-17h2,1h3,(h,37,40)key:vqocbfyudsbdcz-uhfffaoysa-n tm-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation cb1 receptor antagonists such as rimonabant.